Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-GC
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in gastric cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.
Eligibility Criteria
Inclusion Criteria: * \*\*Healthy Controls:\*\* 1. Age \> 18 years; 2. Signed informed consent and willingness to participate in the project. \*\*Gastric Cancer:\*\* 1. Age ≥ 18 years; 2. Performance status (ECOG) score ≤ 1; 3. Histopathologically confirmed gastric adenocarcinoma; 4. No family history of hereditary cancer; 5. No prior anti-tumor treatment; 6. Availability of primary tumor tissue from surgery or biopsy that meets submission requirements; 7. Availability of peripheral blood samples that meet submission requirements; 8. Willingness and ability to sign the informed consent form to participate in the study. Exclusion Criteria: * \*\*Healthy Controls:\*\* 1. Individuals at high risk for hereditary colorectal adenocarcinoma, including family members of the following diseases: family history of gastrointestinal tumors, familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC/LS), and Peutz-Jeghers syndrome (P-J syndrome); 2. History of chronic met